MiNK Therapeutics (INKT) executive compensation, 2026 proxy

Jennifer S. Buell, Ph.D., President and Chief Executive Officer, was paid $2.1M in 2025, up 94% from $1.1M the year before.

Filed
April 30, 2026
Annual meeting
June 17, 2026
Pay year
2025
Named executives
2
CEO total pay
$2.1M+94% vs prior year
2025 CEO Bonus
$350,000Paid in fully vested stock
2025 CEO Option Awards
$1,284,195Grant date fair value
2025 Target Bonus Percentage
50%Expressed as percentage of base salary
Actual Bonus Percentage
156%Percentage of target

How Ph.D. was paid

$2.1M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary21%Bonus17%Option awards62%All other compensation0%

Named executive officers

ExecutiveTotal
Jennifer S. Buell, Ph.D.President and Chief Executive Officer$2,087,881
Christine M. KlaskinConsultant and Former Treasurer$29,822

What changed and why

  • $2.1MPresident and CEO Jennifer S. Buell received total compensation of $2,087,881 for fiscal 2025, compared to $1,078,686 for fiscal 2024.
  • $350KDr. Buell's annual incentive bonus for 2025 was set at $350,000, paid in fully vested stock.
  • 156%The 2025 bonus payout represented 156% of target based on successfully meeting corporate performance goals.
  • $1.3MOption awards granted to Dr. Buell in 2025 had an aggregate grant date fair value of $1,284,195.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.